Brief: Hansa Biopharma Revenue Of SEK 67 Mln In Q3 2022
20/10/2022 07:12
Oct 20 (Reuters) - Hansa Biopharma AB HNSA.ST :
* HANSA BIOPHARMA INTERIM REPORT JANUARY-SEPTEMBER 2022
* TOTAL REVENUE OF SEK 67M IN Q3 2022
* Q3 OPERATING LOSS SEK 154.0 MILLION VERSUS LOSS SEK 148.4
MILLION YEAR AGO
Source text for Eikon: ID:nWkr5fJmsV
Further company coverage: HNSA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Hansa Biopharma AB
See all newsBrief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS